Hepatocyte cell therapy (Heparesc) - Promethera Biosciences

Drug Profile

Hepatocyte cell therapy (Heparesc) - Promethera Biosciences

Alternative Names: Heparesc; HHLivC; Human heterologous liver cells for infusion

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Cytonet
  • Developer Cytonet; Promethera Biosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Liver failure
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Inborn urea cycle disorders
  • Phase II/III Liver failure

Most Recent Events

  • 09 Jan 2017 Promethera Biosciences and LifeLiver enter into a strategic alliance to jointly develop Heparesc® in South Korea
  • 12 Feb 2016 Cytonet terminates the SELICA III phase II trial in Inborn urea cycle disorders in USA and Canada (NCT01195753)
  • 01 Nov 2015 Cytonet completes a phase II trial in Inborn urea cycle disorders (In neonates, In infants, In Children) in Germany (IV) (NCT00718627)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top